Program
sonelokimab
Also written as “Sonelokimab”, “MSB0010841” and “Sonelokimab (M1095)”.
Its studies are mostly in Hidradenitis Suppurativa · Arthritis, Psoriatic · Psoriasis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MoonLake Immunotherapeutics | 104 open or running | phase 3since May 8, 2024 | Apr 4, 2022 | Jan 4, 2027phase 3 · NCT06641089 |
| Bond Avillion 2 Development LP | 10 open or running | phase 2since Dec 20, 2017 | Dec 20, 2017 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since May 23, 2014 | May 23, 2014 | none ahead |
Also a collaborator on its studies: avillion-llp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2014First study: phase 1 study in PsoriasisNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT02156466 · 41 enrolled · Germany
- Dec 20, 2017Bond Avillion 2 Development LP's first study: phase 2 study in PsoriasisNew to Bond Avillion 2 Development LPBond Avillion 2 Development LP · NCT03384745 · 313 enrolled · United States, Bulgaria, Canada and more
- Apr 4, 2022MoonLake Immunotherapeutics's first study: phase 2 study in Hidradenitis SuppurativaNew to MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics · NCT05322473 · 234 enrolled · United States, Bulgaria, Canada and more
- Nov 28, 2022Phase 2 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT05640245 · 207 enrolled · United States, Bulgaria, Czechia and more
- May 8, 20242 phase 3 studies in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT06411899, NCT06411379
- Oct 11, 20242 phase 3 studies in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT06641089, NCT06641076
- Nov 29, 2024Phase 3 study in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT06768671 · 35 enrolled · United States
- May 20, 2025Phase 1 study in Relative BioequivalenceMoonLake Immunotherapeutics · NCT06994936 · 120 enrolled · United Kingdom
- May 28, 2025Phase 3 study in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT07007637 · 835 planned · United States, Belgium, Bulgaria and more
- Oct 20, 2025Phase 3 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT07223138 · 1,560 planned · United States
Ahead
- Jan 4, 2027Primary completion: phase 3 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT06641089
- Feb 4, 2028Primary completion: phase 3 study in Arthritis, PsoriaticMoonLake Immunotherapeutics · NCT07223138
- Jun 13, 2028Primary completion: phase 3 study in Hidradenitis SuppurativaMoonLake Immunotherapeutics · NCT07007637
TargetBeta
“Interleukin 17A inhibitor; Interleukin-17F inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bimekizumabrule | UCB | phase 3 | 43 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07223138Arthritis, Psoriatic · United States | 3 | By invitation | MoonLake Immunotherapeutics | Feb 4, 2028 | 1,560 |
| NCT07007637Hidradenitis Suppurativa · United States, Belgium, Bulgaria and more | 3 | By invitation | MoonLake Immunotherapeutics | Jun 13, 2028 | 835 |
| NCT06994936Relative Bioequivalence · United Kingdom | 1 | Completed | MoonLake Immunotherapeutics | Nov 1, 2025 | 120 |
| NCT06768671Hidradenitis Suppurativa · United States | 3 | Completed | MoonLake Immunotherapeutics | Sep 28, 2026 | 35 |
| NCT06641089Arthritis, Psoriatic · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | MoonLake Immunotherapeutics | Jan 4, 2027 | 600 |
| NCT06641076Arthritis, Psoriatic · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | MoonLake Immunotherapeutics | May 28, 2026 | 960 |
| NCT06411899Hidradenitis Suppurativa · United States, Bulgaria, Canada and more | 3 | Completed | MoonLake Immunotherapeutics | Sep 2, 2025 | 422 |
| NCT06411379Hidradenitis Suppurativa · United States, Belgium, Bulgaria and more | 3 | Completed | MoonLake Immunotherapeutics | Aug 14, 2025 | 418 |
| NCT05640245Arthritis, Psoriatic · United States, Bulgaria, Czechia and more | 2 | Completed | MoonLake Immunotherapeutics | Sep 5, 2023 | 207 |
| NCT05322473Hidradenitis Suppurativa · United States, Bulgaria, Canada and more | 2 | Completed | MoonLake Immunotherapeutics | May 9, 2023 | 234 |
| NCT03384745Psoriasis · United States, Bulgaria, Canada and more | 2 | Completed | Bond Avillion 2 Development LP | Jun 20, 2019 | 313 |
| NCT02156466Psoriasis · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2015 | 41 |
How it is read
Names in the registry
- “Sonelokimab”, 10 entries
- “MSB0010841”, 4 entries
- “Sonelokimab (M1095)”, 1 entry
- “M1095 (Sonelokimab)”, 1 entry
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 5 studies
- Arthritis, Psoriatic, 4 studies
- Psoriasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.